Hand (Lotion)

As a proprietary over-the-counter clinical monograph presentation registered by Derma Glove, Hand supplies active pharmaceutical ingredient Lotion in 70 mL/100mL Lotion; 53.5 g/100mL Gel (NDC 70741-006, 71087-001; SPL 2024-10-09). Clinical prescribing and dispensing guidelines focus on Apply lotion directly onto body and rub with hands until dry.

The active constituent inside Hand—Lotion—functions as a targeted over-the-counter clinical monograph agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Lotion, Hand (registered by Derma Glove, SPL 2024-10-09) specifies proprietary packaging (70741-006, 71087-001) and 70 mL/100mL Lotion; 53.5 g/100mL Gel quality controls alongside a $1.6400/unit NADAC acquisition baseline.

Clinical clearance of Hand (Lotion) (Over-the-Counter Clinical Monograph) relies on local esterase/enzymatic cleavage of hand (lotion) with minimal hepatic cytochrome burden with a Depot mucosal/cutaneous persistence without significant systemic accumulation of Hand (Lotion) half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Hand (Lotion) bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (hand (lotion)).

FDA clinical labeling for Hand (Lotion) restricts administration in documented intolerance or hypersensitivity reaction involving lotion (over-the-counter clinical monograph); concurrent restricted medications flagged in section 4/7 of the hand (lotion) dailymed monograph (1809903-b70741006) across 70 mL/100mL Lotion, 53.5 g/100mL Gel, 53.3 g/100mL Liquid, with self-reported patient tracking dominated by nausea (8.4% of reports), headache (8.1% of reports), dizziness (6.7% of reports).